Q1 2025 Management View CEO Jack Khattar highlighted double-digit revenue growth from core products, excluding legacy products Trokendi XR and Oxtellar XR. These core products achieved a 26% increase ...

The company launched ONAPGO™, a new treatment for Parkinson's disease, in April 2025 and saw significant growth in Qelbree prescriptions, which rose by 22%. Supernus reiterated its full year ...

Supernus' reliance on Qelbree is increasing, but generic competition for other drugs poses challenges. Read why I downgrade SUPN stock from buy to hold.

Supernus Pharmaceuticals Inc (SUPN) reports robust Qelbree sales and strategic advancements, despite facing increased losses ...

First quarter adjusted operating earnings (non-GAAP) (1) increased 16% to $25.9 million. ONAPGO™ (apomorphine hydrochloride) launched in the U.S. in April 2025. The Company reiterates full year ...

“In addition, we are pleased to be bringing ONAPGO to market, another growth driver for our business. ONAPGO represents a novel approach for adults with Parkinson’s disease who are ...

Discussion on ONAPGO's launch highlighted initial positive reception and the expectation of moderate sales contributions in 2025. Analysts expressed cautious optimism, focusing on growth ...

First quarter 2025 total revenues increased 4% to $149.8 million, compared to the same period in 2024. First quarter 2025 total revenues excluding Trokendi XR ® and Oxtellar XR ® net sales (non-GAAP) ...

First quarter 2025 net sales of Qelbree ® increased 44% to $64.7 million, compared to the same period in 2024. First quarter 2025 net sales of GOCOVRI ® increased 16% to $30.7 million, compared to the ...

First quarter adjusted operating earnings (non-GAAP) (1) increased 16% to $25.9 million. ONAPGO™ (apomorphine hydrochloride) launched in the U.S. in April 2025. The Company reiterates full year 2025 ...